Customized cell-based treatment options to combat autoimmunity and restore β-cell function in type 1 diabetes mellitus: Current protocols and future perspectives

Advances in Experimental Medicine and Biology

Volumn 654, Issue , 2010, Pages 641-665

  Fändrich, Fred ^a   Ungefroren, Hendrik ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b NONE

Author keywords

cell; Autoimmune disease; Stem cell; T cell; Tolerance

Indexed keywords

ABATACEPT; BELIMUMAB; C PEPTIDE; COLONY STIMULATING FACTOR 1; GAMMA INTERFERON; INSULIN; MONOCLONAL ANTIBODY CD3; RAPAMYCIN; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; TEPLIZUMAB; ANTIGEN; AUTOANTIGEN;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; CD4+ T LYMPHOCYTE; CELL TRANSDIFFERENTIATION; DENDRITIC CELL; DISEASE PREDISPOSITION; DRUG MECHANISM; DRUG TARGETING; EFFECTOR CELL; EMBRYONIC STEM CELL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN SYNTHESIS; LOW DRUG DOSE; MESENCHYMAL STEM CELL; MONOCYTE; NON HEMATOPOIETIC STEM CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RECURRENT DISEASE; REGULATORY T LYMPHOCYTE; SELF TOLERANCE INDUCING CELL; SPLEEN CELL; STEM CELL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE ACTIVATION; TRANSPLANT ACCEPTANCE INDUCING CELL; TREATMENT RESPONSE; ANIMAL; BIOLOGICAL MODEL; BIOLOGICAL THERAPY; CYTOLOGY; LYMPHOCYTE; METABOLISM; METHODOLOGY; PATHOLOGY; RAT; REVIEW; RISK FACTOR; TIME;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS; AUTOANTIGENS; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; INSULIN-SECRETING CELLS; LYMPHOCYTES; MODELS, BIOLOGICAL; RATS; RISK FACTORS; TIME FACTORS; TISSUE THERAPY;

EID: 77953956753     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-90-481-3271-3_28     Document Type: Article

References (98)

1. Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 2008;57:1759-67.
2. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A, Lowe NJ, Krueger G, Brown MJ, Weiner RS, Birkhofer MJ, Warner GL, Berry KK, Linsley PS, Krueger JG, Ochs HD, Kelley SL, Kang S. CTLA4Ig-mediated blockade of T cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103:1243-52. (Pubitemid 29218294)
3. Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S, Lebwohl MG, Guzzo CA, Jegasothy BV, Linsley PS, Krueger JG. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000;192:681-94.
4. Al Sabbagh A, Nelson PA, Akselband Y, Sobel R, Weiner HL. Antigen-driven peripheral immune tolerance: suppression of experimental autoimmune encephalomyelitis and collageninduced arthritis by aerosol administration of myelin basic protein or type II collagen. Cell Immunol 1996;171:111-9. (Pubitemid 26349132)
5. Anderson M. Autoimmune endocrine disease. Curr Opin Immunol 2002;14:760-4. (Pubitemid 35292423)
6. Apostolou I, von Boehmer H. In vivo instruction of suppressor commitment in naïve T cells. J Exp Med 2004;199:1401-8. (Pubitemid 38685731)
7. Arif S, Tree TI, Astill TP, Tremble JM, Bishop AJ, Dayan CM, Roep BO, Peakman M. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004;113:451-63. (Pubitemid 38544189)
8. Atkinson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 1999;5:601-4. (Pubitemid 29289413)
9. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002;347:911-20.
10. Bingley P, Bonifacio E, Mueller P. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 2003;52:1128-36. (Pubitemid 36523346)
11. Bluestone JA, St. Clair EW, Turka LA. CTLA4Ig: Bridging the basic immunology with clinical application. Immunity 2006;24:233-38.
12. Bonde S, Chan KM, Zavazava N. ES-cell derived hematopoietic cells induce transplantation tolerance. PLoS ONE 2008;3:e3212.
13. Bougnères PF, Landais P, Boisson C, Carel JC, Frament N, Boitard C, Chaussain JL, Bach JF. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 1990;39:1264-72. (Pubitemid 20327064)
14. Boumaza I, Srinivasan S, Witt WT, Feghali-Bostwick C, Dai Y, Garcia-Ocana A, Feili-Hariri M. Autologous bone marrow-derived rat mesenchymal stem cells promote PDX-1 and insulin expression in the islets, alter T cell cytokine pattern and preserve regulatory T cells in the periphery and induce sustained normoglycemia. J Autoimmun 2009;32:33-42.
15. Brem-Exner BG, Sattler C, Hutchinson JA, Koehl GE, Kronenberg K, Farkas S, Inoue S, Blank C, Knechtle SJ, Schlitt HJ, Fändrich F, Geissler EK. Macrophages driven to a novel state of activation have anti-inflammatory properties in mice. J Immunol 2008;180:530-49.
16. Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, von Herrath M. AntiCD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 2006;116:1371-81.
17. Burt RK, Oyama Y, Traynor A, Kenyon NS. Hematopoietic stem cell therapy for type 1 diabetes: induction of tolerance and islet cell neogenesis. Autoimmun Rev 2002;1:133-8. (Pubitemid 38340263)
18. Calderon B, Suri A, Miller MJ, Unanue ER. Dendritic cells in islets of Langerhans constitutively present beta cell derived peptides bound to their class II MHC molecules. Proc Natl Acad Sci USA 2008;105:6121-6. (Pubitemid 351758409)
19. Chaillous L, Lefèvre H, Thivolet C, Boitard C, Lahlou N, Atlan-Gepner C, Bouhanick B, Mogenet A, Nicolino M, Carel JC, Lecomte P, Maréchaud R, Bougnères P, Charbonnel B, Saï P. Oral insulin administration and residual β cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Lancet 2000;356:545-9. (Pubitemid 30611859)
20. Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007;7:622-2.
21. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994;91:123-7. (Pubitemid 24018655)
22. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997;158:2947-54. (Pubitemid 127470558)
23. Chong AS, Shen J, Tao J, Yin D, Kuznetsov A, Hara M, Philipson LH. Reversal of diabetes in non-obese diabetic mice without spleen cell-derived beta cell regeneration. Science 2006;311:1774-5.
24. Diabetes Prevention Trial - Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-91.
25. Domenick MA, Ildstad ST. Impact of bone marrow transplantation on type I diabetes. World J Surg 2001;25:474-80. (Pubitemid 32455201)
26. Ergun-Longmire B, Marker J, Zeidler A, Rapaport R, Raskin P, Bode B, Schatz D, Vargas A, Rogers D, Schwartz S, Malone J, Krischer J, Maclaren NK. Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes. Ann NY Acad Sci 2004;1029: 260-77. (Pubitemid 40298536)
27. Fändrich F, Lin X, Chai GX, Schulze M, Ganten D, Bader M, Holle J, Huang DS, Parwaresch R, Zavazava N, Binas B. Preimplantation-stage stem cells induce allogeneic graft tolerance without supplementary host conditioning. Nat Med 2002;8:171-8. (Pubitemid 34155129)
28. Fändrich F, Zhou X, Schlemminger M, Glass B, Lin X, Dreßke B. Future strategies for tolerance induction: a comparative study between hematopoietic stem cells and macrophages. Hum Immunol 2002;63:805-12. (Pubitemid 35246761)
29. Gagnerault MC, Luan JJ, Lotton C, Lepault F. Pancreatic lymph nodes are required for priming of β cell reactive T cells in NOD mice. J Exp Med 196: 2002;369-77. (Pubitemid 34875666)
30. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor a inhibition. N Engl J Med 2005;353:1114-23. (Pubitemid 41317434)
31. Gottlieb PA and Eisenbarth GS. Diagnosis and treatment of preinsulin dependent diabetes. Annu Rev Med 1998;49:391-405. (Pubitemid 28197462)
32. Greening JE, Tree TI, Kotowicz KT, van Halteren AG, Roep BO, Klein NJ, Peakman M. Processing and presentation of the islet autoantigen GAD by vascular endothelial cells promotes transmigration of autoreactive T cells. Diabetes 2003;52:717-25. (Pubitemid 36323579)
33. Haskins K, Portas M, Bradley B, Wegmann D, Lafferty K. T-lymphocyte clone specific for pancreatic islet antigen. Diabetes 1988;37:1444-8. (Pubitemid 19035999)
34. Haskins K. Pathogenic T cell clones in autoimmune diabetes: more lessons from the NOD mouse. Adv Immunol 2005;87:123-62. (Pubitemid 41133493)
35. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;364:1692-8. (Pubitemid 34547482)
36. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA. A single course of anti-CD3 monoclonal antibody hOKT3γ1 (Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:1763-9. (Pubitemid 40770766)
37. Hill JA, Feuerer M, Tash K, Haxhinasto S, Perez J, Melamed R, Mathis D, Benoist C. Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. Immunity 2007;27:786-800. (Pubitemid 350110546)
38. Hutchinson JA, Brem-Exner BG, Riquelme P, Roelen D, Schulze M, Ivens K, Grabensee B, Witzke O, Philipp T, Renders L, Humpe A, Sotnikova A, Matthäi M, Heumann A, Gövert F, Schulte T, Kabelitz D, Claas FH, Geissler EK, Kunzendorf U, Fändrich F. A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl Int 2008;21:742-54.
39. Hutchinson JA, Riquelme P, Brem-Exner BG, Schulze M, Matthäi M, Renders L, Kunzendorf U, Geissler EK, Fändrich F. Transplant acceptance-inducing cells as an immune-conditioning therapy in renal transplantation. Transpl Int 2008;21:828-41.
40. Hutchinson JA, Gövert F, Riquelme P, Brösen JH, Brem-Exner BG, Matthäi M, Schulze M, Renders L, Kunzendorf U, Geissler EK, Fändrich F. Administration of donor-derived transplant acceptance-inducing cells to the recipients of renal transplants from deceased donors is technically feasible. Clin Transplant 2009;23:140-5.
41. Itakura S, Asari S, Rawson J, Ito T, Todorov I, Liu CP, Sasaki N, Kandeel F, Mullen Y. Mesenchymal stem cells facilitate the induction of mixed hematopoietic chimerism and islet allograft tolerance without GVHD in the rat. Am J Transplant 2007;7:336-46. (Pubitemid 46096326)
42. Iyer SS, Rojas M. Anti-inflammatory effects of mesenchymal stem cells: novel concept for future therapies. Expert Opin Biol Ther 2008;8:569-81. (Pubitemid 351685023)
43. Jaeckel E, Lipes MA, von Boehmer H. Recessive tolerance to preproinsulin 2 reduces but does not abolish type 1 diabetes. Nat Immunol 2004;5:1028-35. (Pubitemid 41057722)
44. Kabelitz D, Geissler EK, Soria B, Schroeder IS, Fändrich F, Chatenoud L. Toward cell-based therapy of type I diabetes. Trends Immunol 2008;29:68-74.
45. Kappler JW, Roehm N, Marrack P. T cell tolerance by clonal elimination in the thymus. Cell 1987;49:273-80.
46. Karounos DG, Bryson JS, Cohen DA. Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD mice. J Clin Invest 1997;100:1344-8. (Pubitemid 27425758)
47. Kaufman DL, Clare-Salzler M, Tian J, Forsthuber T, Ting GS, Robinson P, Atkinson MA, Sercarz EE, Tobin AJ, Lehmann PV. Spontaneous loss of T cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993;366:69-72. (Pubitemid 23345238)
48. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-608. (Pubitemid 41007846)
49. Khadra A, Santamaria P, Edelstein-Keshet L. The role of low avidity T cells in the protection against type 1 diabetes: a modeling investigation. J Theor Biol 2009;256:126-41.
50. Khare SD, Krco CJ, Griffiths MM, Luthra HS, David CS. Oral administration of an immunodominant human collagen peptide modulates collagen-induced arthritis. J Immunol 1995;155:3653-9.
51. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003;4:337-32.
52. Knip M, Veijola R, Virtanen SM, Hyöty H, Vaarala O, Akerblom HK. Environmental triggers and determinants of type 1 diabetes. Diabetes 2005;54 (Suppl 2), S125-36. (Pubitemid 43348458)
53. Koch CA, Geraldes P, Platt JL. Immunosuppression by embryonic stem cells. Stem Cells 2008;26:89-98.
54. Kodama S, Kuhtreiber W, Fujimura S, Dale EA, Faustman DL. Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science 2003;302:1223-7. (Pubitemid 37421029)
55. Koeleman BP, Lie BA, Undlien DE, Dudbridge F, Thorsby E, de Vries RR, Cucca F, Roep BO, Giphart MJ, Todd JA. Genotype effects and epistasis in type 1 diabetes and HLA-DQ trans dimmer associations with disease. Genes Immun 2004;5:381-8. (Pubitemid 39139766)
56. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, Williams GR, Becker JC, Hagerty DT, Moreland LW. Treatment of rheumatoid arthritis by selective inhibition of T cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-15. (Pubitemid 37409707)
57. Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, Steinfeld S, Tindall E, Becker JC, Li T, Nuamah IF, Aranda R, Moreland LW. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-71. (Pubitemid 41117408)
58. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 2004;6:1219-27.
59. Kulmala P, Savola K, Reijonen H, Veijola R, Vähäsalo P, Karjalainen J, Tuomilehto-Wolf E, Ilonen J, Tuomilehto J, Akerblom HK, Knip M. Genetic markers, humoral autoimmunity, and prediction of type 1 diabetes in siblings of affected children. Childhood Diabetes in Finland Study Group. Diabetes 2000;49:48-58. (Pubitemid 30022923)
60. Lampeter EF, Homberg M, Quabeck K, Schaefer UW, Wernet P, Bertrams J, Grosse-Wilde H, Gries FA, Kolb H. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet 1993;341:1243-4. (Pubitemid 23146932)
61. Lampeter EF, McCann SR, Kolb H. Transfer of diabetes type 1 by bone-marrow transplantation. Lancet 1998;351:568-9. (Pubitemid 28077567)
62. Lee RH, Seo MJ, Reger RL, Spees JL, Pulin AA, Olson SD, Prockop DJ. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci U S A 2006;103:17438-43. (Pubitemid 44788987)
63. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4+CD25+ T cells from patients with type 1 diabetes. Diabetes 2005;54:92-99. (Pubitemid 40105099)
64. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci 2008;13:453-61. (Pubitemid 351599757)
65. Mellor AL, Baban B, Chandler P, Marshall B, Jhaver K, Hansen A, Koni PA, Iwashima M, Munn DH. Cutting edge: induced indoleamine 2, 3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 2006;171:1652-5. (Pubitemid 36966447)
66. Melzer B, Wraith DC. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int Immunol 1993;5:1159-65. (Pubitemid 23291165)
67. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007;7:610-21. (Pubitemid 47123548)
68. Nishio J, Gaglia JL, Turvey SE, Campbell C, Benoist C, Mathis D. Islet recovery and reversal of murine type 1 diabetes in the absence of any infused spleen cell contribution. Science 2006;311:1775-78.
69. Oehler JR, Herberman RB, Campbell DA Jr, Djeu JY. Inhibition of rat mixed lymphocyte cultures by suppressor macrophages. Cell Immunol 1977;29:238-50. (Pubitemid 8081602)
70. Ohashi PS. T cell signalling and autoimmunity: molecular mechanisms of disease. Nat Rev Immunol 2002;2:427-38. (Pubitemid 37328750)
71. Oresic M, Simell S, Sysi-Aho M, Näntö-Salonen K, Seppänen-Laakso T, Parikka V, Katajamaa M, Hekkala A, Mattila I, Keskinen P, Yetukuri L, Reinikainen A, Lähde J, Suortti T, Hakalax J, Simell T, Hyöty H, Veijola R, Ilonen J, Lahesmaa R, Knip M, Simell O. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med 2008;205:2975-84.
72. Peakman M, Stevens EJ, Lohmann T, Narendran P, Dromey J, Alexander A, Tomlinson AJ, Trucco M, Gorga JC, Chicz RM. Naturally processed and presented epitopes of the islet cell autoantigen IA-2 eluted from HLA-DR4. J Clin Invest 1999;104:1449-57.
73. Pihoker C, Gilliam LK, Hampe CS, Lernmark A. Autoantibodies in Diabetes. Diabetes 54 Suppl 2005;2:S52-61. (Pubitemid 43343331)
74. Pociaot F, McDermott MF. Genetics of type 1 diabetes mellitus. Genes Immun 2002;3: 235-49. (Pubitemid 38967549)
75. Redondo MJ, RewersM, Yu L, Garg S, Pilcher CC. Genetic determination of islet cell autoimmunity in monozygotic twin, dizygotic twin, and non-twin siblings of patients with type 1 diabetes: prospective twin study. BMJ 1999;318:689-702.
76. Redondo MJ, Fain PR, Eisenbarth GS. Genetics of type 1A diabetes. Recent Prog Horm Res 2001;56:69-89.
77. Schulze M, Fändrich F, Ungefroren H, Kremer B. Adult stem cells - perspectives in treatment of metabolic diseases. Acta Gastro-Enterologica Belgica 2005;68:461-65. (Pubitemid 43067254)
78. Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, Bluestone JA, Eisenbarth GS, Mathis D, Rossini AA, Campbell SE, Kahn R, Kreuwel HT Shoda L. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 2005;23:115-26. (Pubitemid 41169282)
79. Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial - type 1. Diabetes Care 2005;28:1068-76. (Pubitemid 40616615)
80. Sospedra M, Martin R. Antigen-specific therapies in multiple sclerosis. Int Rev Immunol 2005;24:393-413. (Pubitemid 41755154)
81. Steinmann RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003;21:685-711. (Pubitemid 37174545)
82. Suri A, Calderon B, Esparza TJ, Frederick K, Bittner P, Unanue ER. Immunological reversal of autoimmune diabetes without hematopoietic replacement of beta cells. Science 2006;311:1778-80.
83. Suri A, Levisetti MG, Unanue ER. Do the peptide-binding properties of diabetogenic class II molecules explain autoreactivity? Curr Opin Immunol 2008;20:105-10.
84. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: A jack of all trades, master of regulation. Nat Immunol 2008;9:239-44. (Pubitemid 351267321)
85. Tateishi K, He J, Taranova O, Liang G, D'Alessio AC, Zhang Y. Generation of insulinsecreting islet-like clusters from human skin fibroblasts. J Biol Chem 2008 ;283:31601-7.
86. Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996;85:291-7. (Pubitemid 26160699)
87. Tree TI, Peakman M. Autoreactive T cells in human type 1 diabetes. Endocrinol Metab Clin North Am 2004;33:113-33. (Pubitemid 38438426)
88. Tisch R, Wang B. Dysregulation of T cell peripheral tolerance in type 1 diabetes. Adv Immunol 2008;100:125-49.
89. Tivol EA, Boyd SD, McKeon S, Borriello F, Nickerson P, Strom TB, Sharpe AH. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J Immunol 1997;158:5091-4. (Pubitemid 127681209)
90. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, Bailey R, Nejentsev S, Field SF, Payne F, Lowe CE, Szeszko JS, Hafler JP, Zeitels L, Yang JH, Vella A, Nutland S, Stevens HE, Schuilenburg H, Coleman G, Maisuria M, Meadows W, Smink LJ, Healy B, Burren OS, Lam AA, Ovington NR, Allen J, Adlem E, Leung HT, Wallace C, Howson JM, Guja C, Ionescu-Tîrgovişte C. Genetics of Type 1 Diabetes in Finland, Simmonds MJ, Heward JM, Gough SC; Wellcome Trust Case Control Consortium, Dunger DB, Wicker LS, Clayton DG. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007;39:857-64. (Pubitemid 47018195)
91. Tsai S, Shameli A, Santamaria P. CD8+ T cells in type 1 diabetes. Adv Immunol 2008;100: 79-124.
92. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomilehto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Rønningen KS, Guja C, Ionescu-Tîrgovişte C, Savage DA, Maxwell AP, Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB, Wicker LS, Todd JA, Gough SC. Association of the T cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003;423:506-11. (Pubitemid 36648570)
93. Van derWerf N, Kroese FG, Rozing J, Hillebrands JL. Viral infections as potential triggers of type 1 diabetes. Diabetes Metab Res Rev 2007;23:169-83. (Pubitemid 46437842)
94. Verda L, Kim DA, Ikehara S, Statkute L, Bronesky D, Petrenko Y, Oyama Y, He X, Link C, Vahanian NN, Burt RK. Hematopoietic mixed chimerism derived from allogeneic embryonic stem cells prevents autoimmune diabetes mellitus in NOD mice. Stem Cells 2008;26:381-6. (Pubitemid 351413598)
95. Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, Coutinho M, Malmegrim KC, Foss-Freitas MC, Simões BP, Foss MC, Squiers E, Burt RK. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007;297:1568-76. (Pubitemid 46588370)
96. Wegmann DR, Norbury-Glaser M, Daniel D. Insulin-specific T cells are a predominant component of islet infiltrates in pre-diabetic NOD mice. Eur J Immunol 1994;24:1853-7. (Pubitemid 24237557)
97. Young DA, Nickerson-Nutter CL. mTOR-beyond transplantation. Curr Opin Pharmacol 2005;5:418-23.
98. Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA. In vivo reprogramming of adult pancreatic exocrine cells to β cells. Nature 2008;455:627-33.